An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States. Additional coverage: Post-Bulletin Blog

Health.am, 1/18/2012

Tags: Cancer, GI, Mayo Clinic Rochester, Research